Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) FCF Margin (2016 - 2025)

Amicus Therapeutics' FCF Margin history spans 16 years, with the latest figure at 10.35% for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 1316.0% year-over-year to 10.35%, compared with a TTM value of 5.21% through Dec 2025, up 1230.0%, and an annual FY2025 reading of 5.21%, up 1230.0% over the prior year.
  • FCF Margin for Q4 2025 was 10.35% at Amicus Therapeutics, down from 19.42% in the prior quarter.
  • The five-year high for FCF Margin was 19.42% in Q3 2025, with the low at 109.25% in Q1 2021.
  • Average FCF Margin over 5 years is 28.12%, with a median of 19.05% recorded in 2024.
  • Year-over-year, FCF Margin skyrocketed 10194bps in 2023 and then tumbled -3584bps in 2025.
  • Tracing FOLD's FCF Margin over 5 years: stood at 85.01% in 2021, then decreased by -11bps to 94.73% in 2022, then surged by 108bps to 7.21% in 2023, then plummeted by -139bps to 2.81% in 2024, then soared by 469bps to 10.35% in 2025.
  • Per Business Quant, the three most recent readings for FOLD's FCF Margin are 10.35% (Q4 2025), 19.42% (Q3 2025), and 17.12% (Q2 2025).